Immunotherapy as a later-line option for HER2 -altered advanced non-small-cell lung cancer: taxane might be a favorable partner
Future Oncology · 2023
DOI: 10.2217/fon-2022-0879 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, 2023. Verfasst von Yaning Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Aim
To assess the effectiveness of different types of taxanes, including nab-paclitaxel, paclitaxel and docetaxel, and further compare the effectiveness of taxane-based chemotherapy, taxane-based chemotherapy plus angiogenesis inhibitors or taxane-based chemotherapy plus immune checkpoint inhibitors in HER2-altered non-small-cell lung cancer in the second- or third-line setting. Materials & methods: A total of 52 patients were included in the study. Progression-free survival was compared between subgroups.
Results
A clinically meaningful improvement in progression-free survival was observed among patients in the nab-paclitaxel group compared with the docetaxel group. Taxane-based chemotherapy plus immune checkpoint inhibitors achieved longer progression-free survival than taxane-based chemotherapy. There was no difference between taxane-based chemotherapy plus immune checkpoint inhibitors and taxane-based chemotherapy plus angiogenesis inhibitors.
Conclusion
Nab-paclitaxel appears to be a reasonable alternative to docetaxel. Chemotherapy plus immune checkpoint inhibitors might yield more survival benefits than chemotherapy alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Chaoyang District, Beijing, 100021…
- Department of Respiratory Medicine, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China.
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Chaoyang District, Beijing, 100021, China.
- Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Chaoyang District, Beijing,…
ORCID-Profile: Yaning Yang, Yan Wang
Zitieren
APA
Yang, Y., Yang, G., Li, W., Xu, H., Hao, X., Zhang, S., Ai, X., Lei, S., & Wang, Y. (2023). Immunotherapy as a later-line option for HER2 -altered advanced non-small-cell lung cancer: taxane might be a favorable partner. Future Oncology. https://doi.org/10.2217/fon-2022-0879
Vancouver
Yang Y, Yang G, Li W, Xu H, Hao X, Zhang S, et al. Immunotherapy as a later-line option for HER2 -altered advanced non-small-cell lung cancer: taxane might be a favorable partner. Future Oncology. 2023. doi:10.2217/fon-2022-0879
BibTeX
@article{Yang2023,
author = {Yang, Yaning and Yang, Guangjian and Li, Weihua and Xu, Haiyan and Hao, Xuezhi and Zhang, Shuyang and Ai, Xin and Lei, Siyu and Wang, Yan},
title = {Immunotherapy as a later-line option for HER2 -altered advanced non-small-cell lung cancer: taxane might be a favorable partner},
journal = {Future Oncology},
year = {2023},
doi = {10.2217/fon-2022-0879}
}
EUVIMED